TAIWAN: According to the researchers of a large retrospective study reported in JAMA Network Open, one advantage of SGLT2 inhibitors in people with type 2 diabetes (T2D) may be a decreased risk of dry.
Singapore: A meta-analysis of 15 randomized controlled trials of SGLT2 inhibitors for diabetes and non-diabetes patients, showed no significant difference in amputation risk for the various SGLT2.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending Jardiance® (empagliflozin) for the treatment of adults with symptomatic chronic heart failure with reduced ejection fraction (HFrEF), Boehringer Ingelheim and Eli Lilly and Company announced.1